吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (5): 569-572.

吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究

顾亮, 赵恬, 钦光跃

浙江医院呼吸内科,杭州 310013,浙江

收稿日期:2012-01-10 修回日期:2012-04-20 出版日期:2012-05-26 发布日期:2012-05-28
作者简介:顾亮, 男,硕士在读,主治医师,研究方向:肺癌的临床研究。E-mail: jamesgu007@yahoo.com.cn

Comparison of gefitinib and pemetrexed in treatment of advanced non-small cell lung cancer patients who have failed to first-line chemotherapy

GU Liang, ZHAO Tian, QIN Guang-yue

Department of Respiratory, Zhejiang Hospital, Hangzhou 310013, Zhejiang, China

Received:2012-01-10 Revised:2012-04-20 Online:2012-05-26 Published:2012-05-28

摘要/Abstract

摘要： 目的:探讨吉非替尼和培美曲塞单药二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效有无差别。方法: 回顾性分析2009年2月至2011年10月浙江医院呼吸科一线化疗失败后行吉非替尼或培美曲塞二线治疗的晚期NSCLC患者64例,其中吉非替尼组33例,培美曲塞组31例。评价两组患者疾病进展时间及生存期有无差别。结果: 吉非替尼组与培美曲塞组相比无疾病进展生存时间(progressionfree survival, PFS)差别无统计学意义(HR=1.21,95%CI:0.68～2.16, χ²=0.41, P=0.52);培美曲塞组总生存期明显长于吉非替尼组(HR=1.99,95%CI:1.04～3.85, χ⁼4.30, P=0.04);两组患者的毒副反应差别无统计学意义(P＞0.05)。结论:对一线化疗失败的晚期NSCLC,吉非替尼与培美曲塞在延长患者PFS方面无差别,但在总生存时间(overal survival, OS)方面培美曲塞组明显好于吉非替尼组,两组患者毒副反应无差别,都可耐受。

关键词: 吉非替尼, 培美曲塞, 晚期非小细胞肺癌

Abstract: AIM: To evaluate the clinical difference between gefitinib and pemetrexed in treatment of advanced non-small cell lung cancer(NSCLC) patients who have failed to first-line chemotherapy.METHODS: From Feb 2009 to Oct 2011, 64 patients with NSCLC who received gefitinib or pemetrexed for second line chemotherapy were analysised retrospectively. The progression survival time and overall survival time were evaluated.RESULTS:There was no statistics difference between the gefitinib and pemetrexed group for progression free survival time( HR=1.21, 95%CI:0.68-2.16, χ²=0.41, P=0.52).But the overall survival time for patients received pemetrexed was much longer than that patients received gefinitib(HR=1.99 95%CI:1.04-3.85, χ²=4.30, P=0.04).No statistical difference between the two group in side effect(P＞0.05).CONCLUSION: For patients with advanced NSCLC who have failed to first-line chemotherapy, the overall survival time was longer for patients received pemetrexed but not for progression free time in the second line chemotherapy compared with treatment of pemetrexed. The side effect was acceptable and no statistical difference between the two groups was observed.

Key words: Gefitinib, Pemetrexed, Advanced-NSCLC

中图分类号:

R734

顾亮, 赵恬, 钦光跃. 吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究[J]. 中国临床药理学与治疗学, 2012, 17(5): 569-572.

GU Liang, ZHAO Tian, QIN Guang-yue. Comparison of gefitinib and pemetrexed in treatment of advanced non-small cell lung cancer patients who have failed to first-line chemotherapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 569-572.

[1]	王梦瑶，黄洁，刘亚男，杨双，吴淑婷，阳晓燕，叶玲，郭灿，黄志军 . 吉非替尼片在中国健康受试者的人体生物等效性研究[J]. 中国临床药理学与治疗学, 2019, 24(11): 1275-1280.
[2]	李伟文，黎媛，孙蕾，黄公才，赵中伟. 艾迪注射液对培美曲塞联合奈达铂治疗晚期非小细胞肺癌的增效作用[J]. 中国临床药理学与治疗学, 2018, 23(3): 325-328.
[3]	彭晔, 王美芹, 谢娜, 李燕, 卢海燕, 李炳茂. 紫杉醇+顺铂方案联合沙利度胺治疗晚期非小细胞肺癌的临床研究[J]. 中国临床药理学与治疗学, 2013, 18(3): 317-321.
[4]	谢波, 侯远鑫, 张为民, 凌家俊, 林金容, 邓姗姗. 微透析技术应用于Gefitinib药动学采样的可行性研究[J]. 中国临床药理学与治疗学, 2013, 18(12): 1369-1374.
[5]	陈冬云, 赵文英, 吉兆宁. 培美曲塞联合卡铂与吉西他滨联合卡铂一线治疗晚期非鳞非小细胞肺癌的临床观察[J]. 中国临床药理学与治疗学, 2013, 18(12): 1401-1405.
[6]	李苏霞, 杨晓蕾, 陈素秀, 刘洁凡, 全世超. 吉非替尼治疗老年晚期非小细胞肺癌的疗效观察[J]. 中国临床药理学与治疗学, 2013, 18(12): 1410-1413.
[7]	吴志勇, 张肖, 孙胜杰, 张娟. 吉非替尼致间质性肺炎并囊样薄壁空洞形成一例[J]. 中国临床药理学与治疗学, 2012, 17(3): 280-281.
[8]	王丽萍, 王果, 周宏灏. 表皮生长因子受体多态性对酪氨酸激酶抑制剂药效学影响的研究进展[J]. 中国临床药理学与治疗学, 2010, 15(8): 938-944.